Buy & Sell Asana Inc. (ASAN) – Asana Inc. Price Today
Aura AI Summary
Key Stats
- $1.57BMarket Cap
- Consumer CyclicalSector
- -31.41%3M Drawdown
- $1.39BEnterprise Value
- -Dividend Yield
- 0% Buy | 100% SellTrading Activity
- 41 daysTypical Hold Time
Asana Inc. (ASAN) is currently valued at a market capitalization of $1.57B, with an enterprise value of $1.39B. Over the past 52 weeks, Asana Inc. has traded between a low of $5.46 and a high of $19, highlighting its annual price range. Over the past three months, Asana Inc. has recorded a drawdown of -31.41%, reflecting recent price volatility. On average, investors hold Asana Inc. for approximately 41 days, indicating typical investor behavior on the platform.
About Asana Inc.
Asana Inc is a software company. The company provides a platform for work management that helps teams orchestrate work, from daily tasks to cross-functional strategic initiatives. It helps plan marketing campaigns, streamlines processes, manages sales, and manage product launches. Also, the company provides project management and workflow management solutions.
Most Recent News
Enhanced Games debuts in Las Vegas with boosted athletes and a TikTok-friendly sports format
Enhanced Games will hold its first competition in Las Vegas featuring 50 enhanced athletes, including Olympic and world champions, competing in a new sports format designed for digital and social media viewing. The event combines track, pool, and wei...

Phibro Animal Health CEO sold 21,120 shares worth $1.2 million
Phibro Animal Health's CEO recently sold 21,120 shares of the company, generating proceeds of approximately $1.2 million. This insider sale might indicate the CEO's personal financial planning or a strategic move, but it could also raise questions am...

Patient Square buys 210,000 shares of Nektar Pharmaceuticals, signaling strong confidence.
Patient Square has purchased 210,000 shares of Nektar Pharmaceuticals (NKTR), indicating a significant investment move. This purchase reflects Patient Square's confidence in Nektar's future prospects and potential growth. Investors may view this as a...
